Joseph M Connors

List of Publications by Year
in descending order

461 papers	70,417 citations	1980 101 h-index	631 257 g-index
465 all docs	465 docs citations	465 times ranked	53097 citing authors

#	Article	IF	Citations
1	Circos: An information aesthetic for comparative genomics. Genome Research, 2009, 19, 1639-1645.	2.4	9,003
2	Revised Response Criteria for Malignant Lymphoma. Journal of Clinical Oncology, 2007, 25, 579-586.	0.8	4,061
3	Confirmation of the molecular classification of diffuse large B-cell lymphoma by immunohistochemistry using a tissue microarray. Blood, 2004, 103, 275-282.	0.6	3,574
4	The Use of Molecular Profiling to Predict Survival after Chemotherapy for Diffuse Large-B-Cell Lymphoma. New England Journal of Medicine, 2002, 346, 1937-1947.	13.9	3,474
5	Report of an International Workshop to Standardize Response Criteria for Non-Hodgkin's Lymphomas. Journal of Clinical Oncology, 1999, 17, 1244-1244.	0.8	3,209
6	Somatic mutations altering EZH2 (Tyr641) in follicular and diffuse large B-cell lymphomas of germinal-center origin. Nature Genetics, 2010, 42, 181-185.	9.4	1,504
7	Genetics and Pathogenesis of Diffuse Large B-Cell Lymphoma. New England Journal of Medicine, 2018, 378, 1396-1407.	13.9	1,443
8	Frequent mutation of histone-modifying genes in non-Hodgkin lymphoma. Nature, 2011, 476, 298-303.	13.7	1,428
9	Chronic active B-cell-receptor signalling in diffuse large B-cell lymphoma. Nature, 2010, 463, 88-92.	13.7	1,402
10	Results of a Pivotal Phase II Study of Brentuximab Vedotin for Patients With Relapsed or Refractory Hodgkin's Lymphoma. Journal of Clinical Oncology, 2012, 30, 2183-2189.	0.8	1,332
11	Prediction of Survival in Follicular Lymphoma Based on Molecular Features of Tumor-Infiltrating Immune Cells. New England Journal of Medicine, 2004, 351, 2159-2169.	13.9	1,293
12	Oncogenically active MYD88 mutations in human lymphoma. Nature, 2011, 470, 115-119.	13.7	1,292
13	The revised International Prognostic Index (R-IPI) is a better predictor of outcome than the standard IPI for patients with diffuse large B-cell lymphoma treated with R-CHOP. Blood, 2007, 109, 1857-1861.	0.6	1,193
14	Tumor-Associated Macrophages and Survival in Classic Hodgkin's Lymphoma. New England Journal of Medicine, 2010, 362, 875-885.	13.9	1,141
15	Molecular Diagnosis of Primary Mediastinal B Cell Lymphoma Identifies a Clinically Favorable Subgroup of Diffuse Large B Cell Lymphoma Related to Hodgkin Lymphoma. Journal of Experimental Medicine, 2003, 198, 851-862.	4.2	1,002
16	Brentuximab Vedotin (SGN-35) in Patients With Relapsed or Refractory Systemic Anaplastic Large-Cell Lymphoma: Results of a Phase II Study. Journal of Clinical Oncology, 2012, 30, 2190-2196.	0.8	890
17	Introduction of Combined CHOP Plus Rituximab Therapy Dramatically Improved Outcome of Diffuse Large B-Cell Lymphoma in British Columbia. Journal of Clinical Oncology, 2005, 23, 5027-5033.	0.8	874
18	Molecular subtypes of diffuse large B-cell lymphoma arise by distinct genetic pathways. Proceedings of the National Academy of Sciences of the United States of America, 2008, 105, 13520-13525.	3.3	868

#	Article	IF	Citations
19	The proliferation gene expression signature is a quantitative integrator of oncogenic events that predicts survival in mantle cell lymphoma. Cancer Cell, 2003, 3, 185-197.	7.7	848
20	Molecular Diagnosis of Burkitt's Lymphoma. New England Journal of Medicine, 2006, 354, 2431-2442.	13.9	824
21	Concurrent Expression of MYC and BCL2 in Diffuse Large B-Cell Lymphoma Treated With Rituximab Plus Cyclophosphamide, Doxorubicin, Vincristine, and Prednisone. Journal of Clinical Oncology, 2012, 30, 3452-3459.	0.8	824
22	Oncogenic CARD11 Mutations in Human Diffuse Large B Cell Lymphoma. Science, 2008, 319, 1676-1679.	6.0	784
23	ALKâ^' anaplastic large-cell lymphoma is clinically and immunophenotypically different from both ALK+ ALCL and peripheral T-cell lymphoma, not otherwise specified: report from the International Peripheral T-Cell Lymphoma Project. Blood, 2008, 111, 5496-5504.	0.6	784
24	Burkitt lymphoma pathogenesis and therapeutic targets from structural and functional genomics. Nature, 2012, 490, 116-120.	13.7	759
25	An enhanced International Prognostic Index (NCCN-IPI) for patients with diffuse large B-cell lymphoma treated in the rituximab era. Blood, 2014, 123, 837-842.	0.6	693
26	MYC gene rearrangements are associated with a poor prognosis in diffuse large B-cell lymphoma patients treated with R-CHOP chemotherapy. Blood, 2009, 114, 3533-3537.	0.6	566
27	Brentuximab Vedotin with Chemotherapy for Stage III or IV Hodgkinâ€™s Lymphoma. New England Journal of Medicine, 2018, 378, 331-344.	13.9	564
28	MHC class II transactivator CIITA is a recurrent gene fusion partner in lymphoid cancers. Nature, 2011, 471, 377-381.	13.7	551
29	Lymphomas with concurrent BCL2 and MYC translocations: the critical factors associated with survival. Blood, 2009, 114, 2273-2279.	0.6	523
30	Determining cell-of-origin subtypes of diffuse large B-cell lymphoma using gene expression in formalin-fixed paraffin-embedded tissue. Blood, 2014, 123, 1214-1217.	0.6	518
31	Integration of gene mutations in risk prognostication for patients receiving first-line immunochemotherapy for follicular lymphoma: a retrospective analysis of a prospective clinical trial and validation in a population-based registry. Lancet Oncology, The, 2015, 16, 1111-1122.	5.1	483
32	Mantle Cell Lymphoma: A Clinicopathologic Study of 80 Cases. Blood, 1997, 89, 2067-2078.	0.6	448
33	Randomized Comparison of ABVD and MOPP/ABV Hybrid for the Treatment of Advanced Hodgkinâ€™s Disease: Report of an Intergroup Trial. Journal of Clinical Oncology, 2003, 21, 607-614.	0.8	438
34	Gene expression signatures delineate biological and prognostic subgroups in peripheral T-cell lymphoma. Blood, 2014, 123, 2915-2923.	0.6	435
35	Analysis of multiple biomarkers shows that lymphoma-associated macrophage (LAM) content is an independent predictor of survival in follicular lymphoma (FL). Blood, 2005, 106, 2169-2174.	0.6	427
36	De novo transcriptome assembly with ABySS. Bioinformatics, 2009, 25, 2872-2877.	1.8	371

#	Article	IF	Citations
37	ABVD Alone versus Radiation-Based Therapy in Limited-Stage Hodgkin's Lymphoma. New England Journal of Medicine, 2012, 366, 399-408.	13.9	360
38	Molecular Pathogenesis of Hodgkin's Lymphoma: Increasing Evidence of the Importance of the Microenvironment. Journal of Clinical Oncology, 2011, 29, 1812-1826.	0.8	350
39	Mutational and structural analysis of diffuse large B-cell lymphoma using whole-genome sequencing. Blood, 2013, 122, 1256-1265.	0.6	349
40	Diffuse large B-cell lymphoma subgroups have distinct genetic profiles that influence tumor biology and improve gene-expression-based survival prediction. Blood, 2005, 106, 3183-3190.	0.6	348
41	Survival of Patients With Peripheral T-Cell Lymphoma After First Relapse or Progression: Spectrum of Disease and Rare Long-Term Survivors. Journal of Clinical Oncology, 2013, 31, 1970-1976.	0.8	335
42	Prognostic Significance of Diffuse Large B-Cell Lymphoma Cell of Origin Determined by Digital Gene Expression in Formalin-Fixed Paraffin-Embedded Tissue Biopsies. Journal of Clinical Oncology, 2015, 33, 2848-2856.	0.8	334
43	Population-Based Analysis of Incidence and Outcome of Transformed Non-Hodgkin's Lymphoma. Journal of Clinical Oncology, 2008, 26, 5165-5169.	0.8	333
44	Five-year survival and durability results of brentuximab vedotin in patients with relapsed or refractory Hodgkin lymphoma. Blood, 2016, 128, 1562-1566.	0.6	324
45	Whole transcriptome sequencing reveals recurrent NOTCH1 mutations in mantle cell lymphoma. Blood, 2012, 119, 1963-1971.	0.6	313
46	CNS International Prognostic Index: A Risk Model for CNS Relapse in Patients With Diffuse Large B-Cell Lymphoma Treated With R-CHOP. Journal of Clinical Oncology, 2016, 34, 3150-3156.	0.8	313
47	Enteropathy-associated T-cell lymphoma: clinical and histological findings from the International Peripheral T-Cell Lymphoma Project. Blood, 2011, 118, 148-155.	0.6	308
48	Randomized Comparison of ABVD Chemotherapy With a Strategy That Includes Radiation Therapy in Patients With Limited-Stage Hodgkinâ€™s Lymphoma: National Cancer Institute of Canada Clinical Trials Group and the Eastern Cooperative Oncology Group. Journal of Clinical Oncology, 2005, 23, 4634-4642.	0.8	305
49	BCL2 Expression Is a Prognostic Marker for the Activated B-Cellâ€“Like Type of Diffuse Large B-Cell Lymphoma. Journal of Clinical Oncology, 2006, 24, 961-968.	0.8	277
50	Cooperative Epigenetic Modulation by Cancer Amplicon Genes. Cancer Cell, 2010, 18, 590-605.	7.7	263
51	BCL2 Translocation Defines a Unique Tumor Subset within the Germinal Center B-Cell-Like Diffuse Large B-Cell Lymphoma. American Journal of Pathology, 2004, 165, 159-166.	1.9	262
52	Flavopiridol in Untreated or Relapsed Mantle-Cell Lymphoma: Results of a Phase II Study of the National Cancer Institute of Canada Clinical Trials Group. Journal of Clinical Oncology, 2003, 21, 1740-1745.	0.8	261
53	Double-Hit Gene Expression Signature Defines a Distinct Subgroup of Germinal Center B-Cell-Like Diffuse Large B-Cell Lymphoma. Journal of Clinical Oncology, 2019, 37, 190-201.	0.8	257
54	Randomized Phase III Trial of ABVD Versus Stanford V With or Without Radiation Therapy in Locally Extensive and Advanced-Stage Hodgkin Lymphoma: An Intergroup Study Coordinated by the Eastern Cooperative Oncology Group (E2496). Journal of Clinical Oncology, 2013, 31, 684-691.	0.8	256

#	Article	IF	Citations
55	Brentuximab vedotin combined with ABVD or AVD for patients with newly diagnosed Hodgkin's lymphoma: a phase 1, open-label, dose-escalation study. Lancet Oncology, The, 2013, 14, 1348-1356.	5.1	251
56	Point mutations and genomic deletions in CCND1 create stable truncated cyclin D1 mRNAs that are associated with increased proliferation rate and shorter survival. Blood, 2007, 109, 4599-4606.	0.6	226
57	State-of-the-Art Therapeutics: Hodgkin's Lymphoma. Journal of Clinical Oncology, 2005, 23, 6400-6408.	0.8	221
58	Treatment-Related Myelodysplasia and Acute Leukemia in Non-Hodgkinâ€™s Lymphoma Patients. Journal of Clinical Oncology, 2003, 21, 897-906.	0.8	215
59	Molecular and Genetic Characterization of MHC Deficiency Identifies EZH2 as Therapeutic Target for Enhancing Immune Recognition. Cancer Discovery, 2019, 9, 546-563.	7.7	213
60	Durable remissions in a pivotal phase 2 study of brentuximab vedotin in relapsed or refractory Hodgkin lymphoma. Blood, 2015, 125, 1236-1243.	0.6	199
61	Impact of Concordant and Discordant Bone Marrow Involvement on Outcome in Diffuse Large B-Cell Lymphoma Treated With R-CHOP. Journal of Clinical Oncology, 2011, 29, 1452-1457.	0.8	197
62	Primary CNS Lymphoma of T-Cell Origin: A Descriptive Analysis From the International Primary CNS Lymphoma Collaborative Group. Journal of Clinical Oncology, 2005, 23, 2233-2239.	0.8	188
63	Tumor-associated macrophages predict inferior outcomes in classic Hodgkin lymphoma: a correlative study from the E2496 Intergroup trial. Blood, 2012, 120, 3280-3287.	0.6	188
64	Histological Transformation and Progression in Follicular Lymphoma: A Clonal Evolution Study. PLoS Medicine, 2016, 13, e1002197.	3.9	185
65	Recurrent somatic mutations of PTPN1 in primary mediastinal B cell lymphoma and Hodgkin lymphoma. Nature Genetics, 2014, 46, 329-335.	9.4	180
66	Transformation to Aggressive Lymphoma in Nodular Lymphocyte-Predominant Hodgkin's Lymphoma. Journal of Clinical Oncology, 2010, 28, 793-799.	0.8	178
67	Clinicogenetic risk models predict early progression of follicular lymphoma after first-line immunochemotherapy. Blood, 2016, 128, 1112-1120.	0.6	177
68	Brief Chemotherapy and Involved Field Radiation Therapy for Limited-Stage, Histologically Aggressive Lymphoma. Annals of Internal Medicine, 1987, 107, 25.	2.0	176
69	Gene Expressionâ€“Based Model Using Formalin-Fixed Paraffin-Embedded Biopsies Predicts Overall Survival in Advanced-Stage Classical Hodgkin Lymphoma. Journal of Clinical Oncology, 2013, 31, 692-700.	0.8	176
70	Five-year results of brentuximab vedotin in patients with relapsed or refractory systemic anaplastic large cell lymphoma. Blood, 2017, 130, 2709-2717.	0.6	176
71	The architectural pattern of FOXP3-positive T cells in follicular lymphoma is an independent predictor of survival and histologic transformation. Blood, 2010, 115, 289-295.	0.6	173
72	International Prognostic Score in Advanced-Stage Hodgkin's Lymphoma: Altered Utility in the Modern Era. Journal of Clinical Oncology, 2012, 30, 3383-3388.	0.8	171

#	Article	IF	Citations
73	Small Noncleaved, Non-Burkitt's (Burkitt-Like) Lymphoma: Cytogenetics Predict Outcome and Reflect Clinical Presentation. Journal of Clinical Oncology, 1999, 17, 1558-1558.	0.8	169
74	High-grade B-cell lymphoma with MYC and BCL2 and/or BCL6 rearrangements with diffuse large B-cell lymphoma morphology. Blood, 2018, 131, 2060-2064.	0.6	167
75	Acquired TNFRSF14 Mutations in Follicular Lymphoma Are Associated with Worse Prognosis. Cancer Research, 2010, 70, 9166-9174.	0.4	160
76	LMO2 Protein Expression Predicts Survival in Patients With Diffuse Large B-Cell Lymphoma Treated With Anthracycline-Based Chemotherapy With and Without Rituximab. Journal of Clinical Oncology, 2008, 26, 447-454.	0.8	159
77	Genome-wide copy number analysis of Hodgkin Reed-Sternberg cells identifies recurrent imbalances with correlations to treatment outcome. Blood, 2010, 116, 418-427.	0.6	152
78	BCL2 Predicts Survival in Germinal Center B-cellâ€“like Diffuse Large B-cell Lymphoma Treated with CHOP-like Therapy and Rituximab. Clinical Cancer Research, 2011, 17, 7785-7795.	3.2	152
79	Analysis of Heritability and Shared Heritability Based on Genome-Wide Association Studies for Thirteen Cancer Types. Journal of the National Cancer Institute, 2015, 107, djv279.	3.0	152
80	Impact of dual expression of MYC and BCL2 by immunohistochemistry on the risk of CNS relapse in DLBCL. Blood, 2016, 127, 2182-2188.	0.6	145
81	Analysis of secondary chromosomal alterations in 165 cases of follicular lymphoma with t(14;18). Genes Chromosomes and Cancer, 2001, 30, 375-382.	1.5	142
82	Analysis of FOXO1 mutations in diffuse large B-cell lymphoma. Blood, 2013, 121, 3666-3674.	0.6	139
83	Prognostic Factors in Follicular Lymphoma. Journal of Clinical Oncology, 2010, 28, 2902-2913.	0.8	136
84	Diffuse large B-cell lymphoma: reduced CD20 expression is associated with an inferior survival. Blood, 2009, 113, 3773-3780.	0.6	133
85	Gene expression predicts overall survival in paraffin-embedded tissues of diffuse large B-cell lymphoma treated with R-CHOP. Blood, 2008, 112, 3425-3433.	0.6	130
86	Essential Role of the Linear Ubiquitin Chain Assembly Complex in Lymphoma Revealed by Rare Germline Polymorphisms. Cancer Discovery, 2014, 4, 480-493.	7.7	130
87	Prognostic Significance of Anaplastic Lymphoma Kinase (ALK) Protein Expression in Adults With Anaplastic Large Cell Lymphoma. Blood, 1999, 93, 3913-3921.	0.6	130
88	Expression of the FOXP1 transcription factor is strongly associated with inferior survival in patients with diffuse large B-cell lymphoma. Clinical Cancer Research, 2005, 11, 1065-72.	3.2	130
89	Recurrent targets of aberrant somatic hypermutation in lymphoma. Oncotarget, 2012, 3, 1308-1319.	0.8	127
90	Involved-Nodal Radiation Therapy As a Component of Combination Therapy for Limited-Stage Hodgkin's Lymphoma: A Question of Field Size. Journal of Clinical Oncology, 2008, 26, 5170-5174.	0.8	126

#	Article	IF	Citations
91	The E3 ubiquitin ligase UBR5 is recurrently mutated in mantle cell lymphoma. Blood, 2013, 121, 3161-3164.	0.6	124
92	Genome-wide profiling of follicular lymphoma by array comparative genomic hybridization reveals prognostically significant DNA copy number imbalances. Blood, 2009, 113, 137-148.	0.6	122
93	Gene expression profiling of microdissected Hodgkin Reed-Sternberg cells correlates with treatment outcome in classical Hodgkin lymphoma. Blood, 2012, 120, 3530-3540.	0.6	122
94	Organochlorines and risk of nonâ€Hodgkin lymphoma. International Journal of Cancer, 2007, 121, 2767-2775.	2.3	121
95	Follicular lymphoma lacking the t(14;18)(q32;q21): identification of two disease subtypes. British Journal of Haematology, 2003, 120, 424-433.	1.2	118
96	Identification of cytogenetic subgroups and karyotypic pathways of clonal evolution in follicular lymphomas. Genes Chromosomes and Cancer, 2004, 39, 195-204.	1.5	114
97	High-dose chemotherapy and autologous stem cell transplantation for primary refractory or relapsed Hodgkin lymphoma: long-term outcome in the first 100 patients treated in Vancouver. Blood, 2005, 106, 1473-1478.	0.6	112
98	Genetic profiling of MYC and BCL2 in diffuse large B-cell lymphoma determines cell-of-originâ€“specific clinical impact. Blood, 2017, 129, 2760-2770.	0.6	112
99	Treatment of post-transplant lymphoproliferative disease with rituximab monoclonal antibody after lung transplantation. Lancet, The, 1999, 354, 1698-1699.	6.3	111
100	The efficacy and tolerability of adriamycin, bleomycin, vinblastine, dacarbazine and <scp>S</scp>tanford <scp>V</scp> in older <scp>H</scp>odgkin lymphoma patients: a comprehensive analysis from the <scp>N</scp>orth <scp>A</scp>merican intergroup trial <scp>E</scp>2496. British Journal of Haematology, 2013, 161, 76-86.	1.2	111
101	Genome-wide copy-number analyses reveal genomic abnormalities involved in transformation of follicular lymphoma. Blood, 2014, 123, 1681-1690.	0.6	110
102	Comprehensive miRNA sequence analysis reveals survival differences in diffuse large B-cell lymphoma patients. Genome Biology, 2015, 16, 18.	3.8	107
103	Hodgkin lymphoma. Nature Reviews Disease Primers, 2020, 6, 61.	18.1	103
104	New Molecular Assay for the Proliferation Signature in Mantle Cell Lymphoma Applicable to Formalin-Fixed Paraffin-Embedded Biopsies. Journal of Clinical Oncology, 2017, 35, 1668-1677.	0.8	102
105	Genome-wide discovery of somatic regulatory variants in diffuse large B-cell lymphoma. Nature Communications, 2018, 9, 4001.	5.8	102
106	The Prognostic Impact of CD163-Positive Macrophages in Follicular Lymphoma: A Study from the BC Cancer Agency and the Lymphoma Study Association. Clinical Cancer Research, 2015, 21, 3428-3435.	3.2	101
107	High microvessel density determines a poor outcome in patients with diffuse large B-cell lymphoma treated with rituximab plus chemotherapy. Haematologica, 2011, 96, 996-1001.	1.7	100
108	Rapid infusion rituximab in combination with corticosteroid-containing chemotherapy or as maintenance therapy is well tolerated and can safely be delivered in the community setting. Blood, 2007, 109, 4171-4173.	0.6	98

#	Article	IF	Citations
109	Integrative genomic analysis identifies key pathogenic mechanisms in primary mediastinal large B-cell lymphoma. Blood, 2019, 134, 802-813.	0.6	96
110	Longâ€term outcomes for patients with limited stage follicular lymphoma. Cancer, 2010, 116, 3797-3806.	2.0	94
111	Meta-analysis of genome-wide association studies discovers multiple loci for chronic lymphocytic leukemia. Nature Communications, 2016, 7, 10933.	5.8	94
112	Paraffin-based 6-gene model predicts outcome in diffuse large B-cell lymphoma patients treated with R-CHOP. Blood, 2008, 111, 5509-5514.	0.6	93
113	Autologous and Allogeneic Stem-Cell Transplantation for Transformed Follicular Lymphoma: A Report of the Canadian Blood and Marrow Transplant Group. Journal of Clinical Oncology, 2013, 31, 1164-1171.	0.8	92
114	Cell of origin of transformed follicular lymphoma. Blood, 2015, 126, 2118-2127.	0.6	91
115	Treatment strategies, outcomes and prognostic factors in 291 patients with secondary CNS involvement by diffuse large B-cell lymphoma. European Journal of Cancer, 2018, 93, 57-68.	1.3	90
116	Mantle cell lymphoma in the ocular adnexal region. Ophthalmology, 2005, 112, 114-119.	2.5	89
117	Brentuximab vedotin plus bendamustine in relapsed or refractory Hodgkin's lymphoma: an international, multicentre, single-arm, phase 1â€“2 trial. Lancet Oncology, The, 2018, 19, 257-266.	5.1	89
118	A gene signature that distinguishes conventional and leukemic nonnodal mantle cell lymphoma helps predict outcome. Blood, 2018, 132, 413-422.	0.6	89
119	Primary Adrenal Lymphoma. Clinical Lymphoma and Myeloma, 2003, 4, 154-160.	2.1	87
120	Brentuximab vedotin with chemotherapy for stage III/IV classical Hodgkin lymphoma: 3-year update of the ECHELON-1 study. Blood, 2020, 135, 735-742.	0.6	86
121	Treating limited-stage nodular lymphocyte predominant Hodgkin lymphoma similarly to classical Hodgkin lymphoma with ABVD may improve outcome. Blood, 2011, 118, 4585-4590.	0.6	83
122	Brentuximab vedotin with chemotherapy for stage III or IV classical Hodgkin lymphoma (ECHELON-1): 5-year update of an international, open-label, randomised, phase 3 trial. Lancet Haematology,the, 2021, 8, e410-e421.	2.2	83
123	Allogeneic haematopoietic stem-cell transplantation for relapsed and refractory aggressive histology non-Hodgkin lymphoma*. British Journal of Haematology, 2005, 131, 223-230.	1.2	78
124	Diffuse large Bâ€cell lymphoma with testicular involvement: outcome and risk of <scp>CNS</scp> relapse in the rituximab era. British Journal of Haematology, 2017, 176, 210-221.	1.2	78
125	Early progression after bendamustine-rituximab is associated with high risk of transformation in advanced stage follicular lymphoma. Blood, 2019, 134, 761-764.	0.6	77
126	Advanced-stage nodular lymphocyte predominant Hodgkin lymphoma compared with classical Hodgkin lymphoma: a matched pair outcome analysis. Blood, 2014, 123, 3567-3573.	0.6	76

#	Article	IF	Citations
127	Active Idiotypic Vaccination Versus Control Immunotherapy for Follicular Lymphoma. Journal of Clinical Oncology, 2014, 32, 1797-1803.	0.8	75
128	MACOP-B and VACOP-B in diffuse large cell lymphomas and MOPP/ABV in Hodgkin's disease. Annals of Oncology, 1991, 2, 17-23.	0.6	74
129	High-resolution architecture and partner genes of MYC rearrangements in lymphoma with DLBCL morphology. Blood Advances, 2018, 2, 2755-2765.	2.5	74
130	Outcome prediction by extranodal involvement, IPI, Râ€ IPI, and NCCNâ€ IPI in the PET/CT and rituximab era: A <scp>D</scp>anishâ€“<scp>C</scp>anadian study of 443 patients with diffuseâ€ large <scp>B</scp>â€cell lymphoma. American Journal of Hematology, 2015, 90, 1041-1046.	2.0	71
131	Diffuse large B-cell lymphoma with involvement of the kidney: outcome and risk of central nervous system relapse. Haematologica, 2011, 96, 1002-1007.	1.7	69
132	Prognostic Significance of Bax Protein Expression in Diffuse Aggressive Non-Hodgkin's Lymphoma. Blood, 1997, 90, 3173-3178.	0.6	65
133	The Spectrum of Lymphoma with 8q24 Aberrations: A Clinical, Pathological and Cytogenetic Study of 87 Consecutive Cases. Leukemia and Lymphoma, 2004, 45, 519-528.	0.6	65
134	Treatment and Outcomes in Patients With Primary Cutaneous B-Cell Lymphoma: The BC Cancer Agency Experience. International Journal of Radiation Oncology Biology Physics, 2013, 87, 719-725.	0.4	65
135	The number of extranodal sites assessed by PET/CT scan is a powerful predictor of CNS relapse for patients with diffuse large B-cell lymphoma: An international multicenter study of 1532 patients treated with chemoimmunotherapy. European Journal of Cancer, 2017, 75, 195-203.	1.3	65
136	Molecular classification of primary mediastinal large B-cell lymphoma using routinely available tissue specimens. Blood, 2018, 132, 2401-2405.	0.6	64
137	CHOP-R therapy overcomes the adverse prognostic influence of BCL-2 expression in diffuse large B-cell lymphoma. Leukemia and Lymphoma, 2007, 48, 1102-1109.	0.6	63
138	Correlations between BCL6 rearrangement and outcome in patients with diffuse large B-cell lymphoma treated with CHOP or R-CHOP. Haematologica, 2010, 95, 96-101.	1.7	63
139	Identification of Primary Mediastinal Large B-cell Lymphoma at Nonmediastinal Sites by Gene Expression Profiling. American Journal of Surgical Pathology, 2015, 39, 1322-1330.	2.1	63
140	High-Dose Therapy and Autologous Hematopoietic Stem-Cell Transplantation Does Not Increase the Risk of Second Neoplasms for Patients With Hodgkin's Lymphoma: A Comparison of Conventional Therapy Alone Versus Conventional Therapy Followed by Autologous Hematopoietic Stem-Cell Transplantation. Journal of Clinical Oncology, 2005, 23, 7994-8002.	0.8	62
141	TBL1XR1/TP63: a novel recurrent gene fusion in B-cell non-Hodgkin lymphoma. Blood, 2012, 119, 4949-4952.	0.6	60
142	Reduced telomere length variation in healthy oldest old. Mechanisms of Ageing and Development, 2008, 129, 638-641.	2.2	59
143	Outcomes in splenic marginal zone lymphoma: analysis of 107 patients treated in British Columbia. British Journal of Haematology, 2015, 169, 520-527.	1.2	58
144	Assessment of Capture and Amplicon-Based Approaches for the Development of a Targeted Next-Generation Sequencing Pipeline to Personalize Lymphoma Management. Journal of Molecular Diagnostics, 2018, 20, 203-214.	1.2	58

#	Article	IF	Citations
145	Long-term results of PET-guided radiation in patients with advanced-stage diffuse large B-cell lymphoma treated with R-CHOP. Blood, 2021, 137, 929-938.	0.6	57
146	Evaluation of the Risk of Relapse in Classical Hodgkin Lymphoma at Event-Free Survival Time Points and Survival Comparison With the General Population in British Columbia. Journal of Clinical Oncology, 2016, 34, 2493-2500.	0.8	56
147	Identification of highâ€risk <scp>DUSP</scp>22â€rearranged <scp>ALK</scp>â€negative anaplastic large cell lymphoma. British Journal of Haematology, 2019, 186, e28-e31.	1.2	56
148	Primary paranasal sinus lymphoma: natural history and improved outcome with central nervous system chemoprophylaxis. Leukemia and Lymphoma, 2005, 46, 1721-1727.	0.6	55
149	Hodgkin's Lymphoma in Adolescents. Journal of Clinical Oncology, 2006, 24, 2520-2526.	0.8	55
150	Cytogenetic Analysis in Mantle Cell Lymphoma: A Review of 214 Cases. Leukemia and Lymphoma, 2002, 43, 783-791.	0.6	54
151	CD20 mutations involving the rituximab epitope are rare in diffuse large B-cell lymphomas and are not a significant cause of R-CHOP failure. Haematologica, 2009, 94, 423-427.	1.7	53
152	Prognostic implications of extranodal involvement in patients with diffuse large B-cell lymphoma treated with rituximab and cyclophosphamide, doxorubicin, vincristine, and prednisone. Leukemia and Lymphoma, 2010, 51, 1-10.	0.6	53
153	A new biologic prognostic model based on immunohistochemistry predicts survival in patients with diffuse large B-cell lymphoma. Blood, 2012, 120, 2290-2296.	0.6	53
154	High resolution analysis of follicular lymphoma genomes reveals somatic recurrent sites of copyâ€neutral loss of heterozygosity and copy number alterations that target single genes. Genes Chromosomes and Cancer, 2010, 49, 669-681.	1.5	51
155	GBVâ€C/hepatitis G virus infection and nonâ€Hodgkin lymphoma: a case control study. International Journal of Cancer, 2010, 126, 2885-2892.	2.3	51
156	Bone Marrow Involvement in T-Cellâ€“Rich B-Cell Lymphoma. American Journal of Clinical Pathology, 1997, 108, 570-578.	0.4	50
157	Prognostic significance of secondary cytogenetic alterations in follicular lymphomas. Genes Chromosomes and Cancer, 2008, 47, 1038-1048.	1.5	50
158	International Assessment of Event-Free Survival at 24 Months and Subsequent Survival in Peripheral T-Cell Lymphoma. Journal of Clinical Oncology, 2017, 35, 4019-4026.	0.8	50
159	Limitedâ€stage diffuse large Bâ€cell lymphoma treated with abbreviated systemic therapy and consolidation radiotherapy. Cancer, 2012, 118, 4156-4165.	2.0	49
160	The treatment of primary central nervous system lymphoma in 122 immunocompetent patients. Cancer, 2005, 103, 1008-1017.	2.0	48
161	Prognostic Model to Predict Post-Autologous Stem-Cell Transplantation Outcomes in Classical Hodgkin Lymphoma. Journal of Clinical Oncology, 2017, 35, 3722-3733.	0.8	48
162	Outcomes in adolescents and young adults with Hodgkin lymphoma treated on US cooperative group protocols: An adult intergroup (E2496) and Children's Oncology Group (COG AHOD0031) comparative analysis. Cancer, 2018, 124, 136-144.	2.0	47

#	Article	IF	Citations
163	Long-term disease-free survival of patients with advanced follicular lymphoma after allogeneic bone marrow transplantation. British Journal of Haematology, 2004, 127, 311-321.	1.2	46
164	Hand-assisted laparoscopic splenectomy versus open splenectomy for massive splenomegaly: 20-year experience at a Canadian centre. Canadian Journal of Surgery, 2011, 54, 189-193.	0.5	46
165	Treatment and Outcomes of Primary Breast Lymphoma. Clinical Breast Cancer, 2012, 12, 412-419.	1.1	46
166	Comparison of American Joint Committee on Cancer TNM-based Staging System (7th edition) and Ann Arbor Classification for Predicting Outcome in Ocular Adnexal Lymphoma. Orbit, 2014, 33, 23-28.	0.5	46
167	TMEM30A loss-of-function mutations drive lymphomagenesis and confer therapeutically exploitable vulnerability in B-cell lymphoma. Nature Medicine, 2020, 26, 577-588.	15.2	46
168	Novel agents improve survival of transplant patients with multiple myeloma including those with high-risk disease defined by early relapse (<12 months). Leukemia and Lymphoma, 2011, 52, 34-41.	0.6	45
169	Vascularization predicts overall survival and risk of transformation in follicular lymphoma. Haematologica, 2010, 95, 2157-2160.	1.7	44
170	HLA-DR protein status predicts survival in patients with diffuse large B-cell lymphoma treated on the MACOP-B chemotherapy regimen. Leukemia and Lymphoma, 2007, 48, 542-546.	0.6	43
171	Hodgkin Lymphoma in Pregnancy. Current Hematologic Malignancy Reports, 2013, 8, 211-217.	1.2	43
172	Genetic Variation in Healthy Oldest-Old. PLoS ONE, 2009, 4, e6641.	1.1	42
173	Clinical Manifestations and Natural History of Hodgkinâ€™s Lymphoma. Cancer Journal (Sudbury, Mass), 2009, 15, 124-128.	1.0	42
174	Rituximab with highâ€dose methotrexate in primary central nervous system lymphoma. American Journal of Hematology, 2015, 90, 1149-1154.	2.0	41
175	COO and MYC/BCL2 status do not predict outcome among patients with stage I/II DLBCL: a retrospective multicenter study. Blood Advances, 2019, 3, 2013-2021.	2.5	40
176	Multicolour fluorescence in situ hybridization analysis of t(14;18)-positive follicular lymphoma and correlation with gene expression data and clinical outcome. British Journal of Haematology, 2003, 122, 745-759.	1.2	39
177	Outcome of Patients With Non-Hodgkin Lymphomas With Concurrent MYC and BCL2 Rearrangements Treated With CODOX-M/IVAC With Rituximab Followed by Hematopoietic Stem Cell Transplantation. Clinical Lymphoma, Myeloma and Leukemia, 2015, 15, 341-348.	0.2	39
178	Risk assessment in the management of newly diagnosed classical Hodgkin lymphoma. Blood, 2015, 125, 1693-1702.	0.6	38
179	Anaplastic large cell lymphoma: a clinicopathologic analysis. , 1999, 17, 137-148.		37
180	Genetic Variation in H2AFX Contributes to Risk of Nonâ€“Hodgkin Lymphoma. Cancer Epidemiology Biomarkers and Prevention, 2007, 16, 1098-1106.	1.1	37

#	Article	IF	Citations
181	Five-year follow-up of brentuximab vedotin combined with ABVD or AVD for advanced-stage classical Hodgkin lymphoma. Blood, 2017, 130, 1375-1377.	0.6	37
182	Secondary Breast Cancer Risk by Radiation Volume in Women With Hodgkin Lymphoma. International Journal of Radiation Oncology Biology Physics, 2017, 97, 35-41.	0.4	37
183	Treatment of Elderly Hodgkin's Lymphoma Patients with a Novel 5-drug Regimen (ODBEP): A Phase II Study. Leukemia and Lymphoma, 2002, 43, 1395-1402.	0.6	36
184	Frequent occurrence of deletions in primary mediastinal Bâ€cell lymphoma. Genes Chromosomes and Cancer, 2007, 46, 1090-1097.	1.5	36
185	Interaction between organochlorines and the AHR gene, and risk of non-Hodgkin lymphoma. Cancer Causes and Control, 2010, 21, 11-22.	0.8	36
186	Automated Analysis of Multidimensional Flow Cytometry Data Improves Diagnostic Accuracy Between Mantle Cell Lymphoma and Small Lymphocytic Lymphoma. American Journal of Clinical Pathology, 2012, 137, 75-85.	0.4	36
187	Primary, Unilateral Ocular Adnexal Lymphoma: Disease Progression and Long-Term Survival. Ophthalmic Plastic and Reconstructive Surgery, 2011, 27, 405-409.	0.4	35
188	Fludarabine and rituximab for relapsed or refractory hairy cell leukemia. Blood, 2012, 119, 1988-1991.	0.6	35
189	Hodgkin's Lymphoma â€" The Great Teacher. New England Journal of Medicine, 2011, 365, 264-265.	13.9	34
190	Prognostic factors for advancedâ€stage human immunodeficiency virusâ€associated classical Hodgkin lymphoma treated with doxorubicin, bleomycin, vinblastine, and dacarbazine plus combined antiretroviral therapy: A multiâ€institutional retrospective study. Cancer, 2015, 121, 423-431.	2.0	34
191	Uterine, but not ovarian, female reproductive organ involvement at presentation by diffuse large Bâ€cell lymphoma is associated with poor outcomes and a high frequency of secondary <scp>CNS</scp> involvement. British Journal of Haematology, 2016, 175, 876-883.	1.2	34
192	Splenectomy vs. alpha interferon: A randomized study in patients with previously untreated hairy cell leukemia. American Journal of Hematology, 1992, 41, 13-18.	2.0	33
193	Radioimmunotherapy â€" Hot New Treatment for Lymphoma. New England Journal of Medicine, 2005, 352, 496-498.	13.9	33
194	Gemcitabine, dexamethasone, and cisplatin (GDP) is an effective and well-tolerated salvage therapy for relapsed/refractory diffuse large B-cell lymphoma and Hodgkin lymphoma. Leukemia and Lymphoma, 2017, 58, 324-332.	0.6	32
195	Hodgkin Lymphoma: Current Status and Clinical Trial Recommendations. Journal of the National Cancer Institute, 2017, 109, djw249.	3.0	31
196	FOXP1 expression is a prognostic biomarker in follicular lymphoma treated with rituximab and chemotherapy. Blood, 2018, 131, 226-235.	0.6	31
197	Diffuse Malignant Lymphoma with Cerebriform Nuclei: A B-Cell Lymphoma Studied with Monoclonal Antibodies. American Journal of Clinical Pathology, 1985, 83, 753-759.	0.4	30
198	Characterization of the recurrent translocation t(1;1)(p36.3;q21.1-2) in non-Hodgkin lymphoma by multicolor banding and fluorescence in situ hybridization analysis. Genes Chromosomes and Cancer, 2003, 36, 375-381.	1.5	30

#	Article	IF	Citations
199	Salvage Therapy with Allogeneic Stem Cell Transplantation Results in Better Outcome for Patients with Relapsed/Refractory Follicular Lymphoma Compared to Those with Transformed Non-Hodgkin Lymphoma: A Population-Based Comparative Study.. Blood, 2008, 112, 975-975.	0.6	29
200	Results of a Pivotal Phase 2 Study of Brentuximab Vedotin (SGN-35) in Patients with Relapsed or Refractory Hodgkin Lymphoma. Blood, 2010, 116, 283-283.	0.6	29
201	The Outcome of Primary Mediastinal Large B-Cell Lymphoma (PMBCL) in the R-CHOP Treatment Era. Blood, 2012, 120, 303-303.	0.6	29
202	Genomic testing to determine drug response: measuring preferences of the public and patients using Discrete Choice Experiment (DCE). BMC Health Services Research, 2013, 13, 454.	0.9	28
203	R-CHOP with Etoposide Substituted for Doxorubicin (R-CEOP): Excellent Outcome in Diffuse Large B Cell Lymphoma for Patients with a Contraindication to Anthracyclines.. Blood, 2009, 114, 408-408.	0.6	28
204	Haematopoietic stem cell transplantation as primary therapy of sporadic adult Burkitt lymphoma*. British Journal of Haematology, 2006, 133, 634-637.	1.2	27
205	Hepatitis C virus and risk of nonâ€Hodgkin lymphoma in British Columbia, Canada. International Journal of Cancer, 2008, 122, 630-633.	2.3	27
206	Genetic variation in the NBS1, MRE11, RAD50 and BLM genes and susceptibility to non-Hodgkin lymphoma. BMC Medical Genetics, 2009, 10, 117.	2.1	27
207	Validation of a Prognostic Model to Assess the Risk of CNS Disease in Patients with Aggressive B-Cell Lymphoma. Blood, 2014, 124, 394-394.	0.6	27
208	Delineation of a minimal region of deletion at 6q16.3 in follicular lymphoma and construction of a bacterial artificial chromosome contig spanning a 6-megabase region of 6q16-q21. Genes Chromosomes and Cancer, 2004, 40, 60-65.	1.5	26
209	Effect of Place of Residence and Treatment on Survival Outcomes in Patients With Diffuse Large B-Cell Lymphoma in British Columbia. Oncologist, 2014, 19, 283-290.	1.9	26
210	Toward Personalized Lymphoma Immunotherapy: Identification of Common Driver Mutations Recognized by Patient CD8+ T Cells. Clinical Cancer Research, 2016, 22, 2226-2236.	3.2	26
211	Site of central nervous system (CNS) relapse in patients with diffuse large Bâ€cell lymphoma (DLBCL) by the CNSâ€IPI risk model. British Journal of Haematology, 2017, 179, 508-510.	1.2	26
212	Brentuximab Vedotin plus Chemotherapy in North American Subjects with Newly Diagnosed Stage III or IV Hodgkin Lymphoma. Clinical Cancer Research, 2019, 25, 1718-1726.	3.2	26
213	Cost-Effectiveness of the Addition of Rituximab to CHOP Chemotherapy in First-Line Treatment for Diffuse Large B-Cell Lymphoma in a Population-Based Observational Cohort in British Columbia, Canada. Value in Health, 2010, 13, 703-711.	0.1	25
214	Oral fludarabine and rituximab as initial therapy for chronic lymphocytic leukemia or small lymphocytic lymphoma: population-based experience matches clinical trials. Leukemia and Lymphoma, 2012, 53, 77-82.	0.6	24
215	An RCOR1 lossâ€“associated gene expression signature identifies a prognostically significant DLBCL subgroup. Blood, 2015, 125, 959-966.	0.6	24
216	Three-Year Survival Results From An Ongoing Phase 2 Study Of Brentuximab Vedotin In Patients With Relapsed Or Refractory Systemic Anaplastic Large Cell Lymphoma. Blood, 2013, 122, 1809-1809.	0.6	24

#	Article	IF	Citations
217	The evolving role of etoposide in the management of lymphomas and hodgkin's disease. Cancer, 1991, 67, 271-280.	2.0	23
218	Clinical Significance of the t(14;18) AndBCL2Overexpression in Follicular Large Cell Lymphoma. Leukemia and Lymphoma, 2000, 36, 513-523.	0.6	23
219	Challenging Problems: Coincident Pregnancy, HIV Infection, and Older Age. Hematology American Society of Hematology Education Program, 2008, 2008, 334-339.	0.9	23
220	Allogeneic haematopoietic stem cell transplantation for chronic lymphocytic leukaemia: outcome in a 20â€year cohort. British Journal of Haematology, 2012, 158, 174-185.	1.2	23
221	Mapping the human T cell repertoire to recurrent driver mutations in MYD88 and EZH2 in lymphoma. OncoImmunology, 2017, 6, e1321184.	2.1	23
222	Phase 2 Trial of Interim PET Scan-Tailored Therapy in Patients with Advanced Stage Diffuse Large B-Cell Lymphoma (DLBCL) in British Columbia (BC). Blood, 2014, 124, 392-392.	0.6	23
223	Mantle cell lymphoma: report of the 2010 Mantle Cell Lymphoma Consortium Workshop. Leukemia and Lymphoma, 2011, 52, 24-33.	0.6	22
224	Positron Emission Tomography in the Management of Hodgkin Lymphoma. Hematology American Society of Hematology Education Program, 2011, 2011, 317-322.	0.9	22
225	Molecular features of a large cohort of primary central nervous system lymphoma using tissue microarray. Blood Advances, 2019, 3, 3953-3961.	2.5	22
226	Uncovering novel inter- and intrachromosomal chromosome 1 aberrations in follicular lymphomas by using an innovative multicolor banding technique. Genes Chromosomes and Cancer, 2002, 34, 201-210.	1.5	21
227	Physical activity, obesity and survival in diffuse large Bâ€cell and follicular lymphoma cases. British Journal of Haematology, 2017, 178, 442-447.	1.2	21
228	Genetic Variation in Cell Death Genes and Risk of Non-Hodgkin Lymphoma. PLoS ONE, 2012, 7, e31560.	1.1	21
229	Outcome of primary cutaneous anaplastic large cell lymphoma: a 20â€year British Columbia Cancer Agency experience. British Journal of Haematology, 2017, 176, 234-240.	1.2	20
230	Advanced Stage Classical Hodgkin Lymphoma Patients with a Negative PET-Scan Following Treatment with ABVD Have Excellent Outcomes without the Need for Consolidative Radiotherapy Regardless of Disease Bulk at Presentation. Blood, 2015, 126, 579-579.	0.6	20
231	Three-Year Follow-Up Data and Characterization Of Long-Term Remissions From An Ongoing Phase 2 Study Of Brentuximab Vedotin In Patients With Relapsed Or Refractory Hodgkin Lymphoma. Blood, 2013, 122, 4382-4382.	0.6	19
232	Impact of MYC and BCL2 structural variants in tumors of DLBCL morphology and mechanisms of false-negative MYC IHC. Blood, 2021, 137, 2196-2208.	0.6	18
233	Development of adapted RECIST criteria to assess response in lymphoma and their comparison to the International Workshop Criteria. Leukemia and Lymphoma, 2007, 48, 513-520.	0.6	17
234	Elevated circulating t(14;18) translocation levels prior to diagnosis of follicular lymphoma. Blood, 2010, 116, 6146-6147.	0.6	17

#	Article	IF	Citations
235	A Canadian Evidence-Based Guideline for the First-Line Treatment of Follicular Lymphoma: Joint Consensus of the Lymphoma Canada Scientific Advisory Board. Clinical Lymphoma, Myeloma and Leukemia, 2015, 15, 59-74.	0.2	17
236	Long-term outcomes of R-CEOP show curative potential in patients with DLBCL and a contraindication to anthracyclines. Blood Advances, 2021, 5, 1483-1489.	2.5	17
237	Cure of ommaya reservoir associated staphylococcus epidermidis ventriculitis with a simple regimen of vancomycin and rifampin without reservoir removal. Medical and Pediatric Oncology, 1982, 10, 549-552.	1.0	16
238	TREATMENT CONSIDERATIONS IN THE ELDERLY PATIENT WITH LYMPHOMA. Hematology/Oncology Clinics of North America, 1997, 11, 949-961.	0.9	16
239	Favorable Outcomes from Allogeneic and Autologous Stem Cell Transplantation for Patients with Transformed Nonfollicular Indolent Lymphoma. Biology of Blood and Marrow Transplantation, 2014, 20, 1813-1818.	2.0	16
240	Interim PET-directed therapy in limited-stage Hodgkin lymphoma initially treated with ABVD. Haematologica, 2018, 103, e590-e593.	1.7	16
241	Brentuximab vedotin for the treatment of patients with relapsed or refractory Hodgkin lymphoma after autologous stem cell transplantation. British Journal of Haematology, 2020, 188, 540-549.	1.2	16
242	Limited-Stage Diffuse Large B-Cell Lymphoma (DLBCL) Patients with a Negative Pet Scan Following Three Cycles of R-CHOP Can Be Effectively Treated with Abbreviated Chemoimmunotherapy Alone.. Blood, 2007, 110, 787-787.	0.6	16
243	Gemcitabine, Dexamethasone, and Cisplatin (GDP) Is An Effective and Well-Tolerated out-Patient Salvage Therapy for Relapsed/Refractory Diffuse Large B-Cell Lymphoma (DLBCL) and Hodgkin Lymphoma (HL). Blood, 2010, 116, 113-113.	0.6	16
244	Hodgkinâ€™s Lymphoma: The Hazards of Success. Journal of Clinical Oncology, 2003, 21, 3388-3390.	0.8	15
245	Genomeâ€wide methylation analyses identify a subset of mantle cell lymphoma with a high number of methylated CpGs and aggressive clinicopathological features. International Journal of Cancer, 2013, 133, 2852-2863.	2.3	15
246	Clinical characteristics and outcomes of patients with Hodgkin lymphoma with central nervous system involvement: An international multicenter collaboration. American Journal of Hematology, 2016, 91, 894-899.	2.0	15
247	The Super-Seniors Study: Phenotypic characterization of a healthy 85+ population. PLoS ONE, 2018, 13, e0197578.	1.1	15
248	Excellent realâ€world outcomes of adults with Burkitt lymphoma treated with <scp>CODOX</scp>â€M/<scp>IVAC</scp> plus or minus rituximab. British Journal of Haematology, 2018, 181, 782-790.	1.2	15
249	Comparison of the NCCNâ€IPI, the IPI and PIT scores as prognostic tools in peripheral Tâ€cell lymphomas. British Journal of Haematology, 2019, 186, e24-e27.	1.2	15
250	Long-term outcomes for patients with limited-stage follicular lymphoma: update of a population-based study. Blood, 2020, 136, 1006-1010.	0.6	15
251	Impact of time from diagnosis to initiation of curative chemotherapy on survival of patients with diffuse large B-cell lymphoma. Leukemia and Lymphoma, 2016, 57, 276-282.	0.6	14
252	Treatment patterns and costs of care for patients with relapsed and refractory Hodgkin lymphoma treated with brentuximab vedotin in the United States: A retrospective cohort study. PLoS ONE, 2017, 12, e0180261.	1.1	14

#	Article	IF	Citations
253	Addition of Rituximab to CHOP Chemotherapy Significantly Improves Survival of Patients with Transformed Lymphoma.. Blood, 2007, 110, 790-790.	0.6	14
254	Non-Hodgkin lymphoma: the clinician's perspectiveâ€”a view from the receiving end. Modern Pathology, 2013, 26, S111-S118.	2.9	13
255	Diffuse large B-cell lymphoma cell-of-origin classification using the Lymph2Cx assay in the context of BCL2 and MYC expression status. Leukemia and Lymphoma, 2016, 57, 717-720.	0.6	13
256	Brentuximab Vedotin for Stage III or IV Hodgkinâ€™s Lymphoma. New England Journal of Medicine, 2018, 378, 1558-1561.	13.9	13
257	Brentuximab vedotin and bendamustine produce high complete response rates in patients with chemotherapy refractory Hodgkin lymphoma. British Journal of Haematology, 2018, 180, 757-760.	1.2	13
258	Genomic predictors of central nervous system relapse in primary testicular diffuse large B-cell lymphoma. Blood, 2021, 137, 1256-1259.	0.6	13
259	Gene Expression Differences between Low and High Stage Diffuse Large B Cell Lymphoma (DLBCL).. Blood, 2006, 108, 809-809.	0.6	13
260	Complete Remissions with Brentuximab Vedotin (SGN-35) in Patients with Relapsed or Refractory Systemic Anaplastic Large Cell Lymphoma. Blood, 2010, 116, 961-961.	0.6	13
261	The Combination of Brentuximab Vedotin (Bv) and Bendamustine (B) Demonstrates Marked Activity in Heavily Treated Patients with Relapsed or Refractory Hodgkin Lymphoma (HL) and Anaplastic Large T-Cell Lymphoma (ALCL): Results of an International Multi Center Phase I/II Experience. Blood, 2015, 126, 586-586.	0.6	13
262	Alemtuzumab in clinical practice: A British Columbia experience. Leukemia and Lymphoma, 2008, 49, 218-226.	0.6	12
263	B Cells With High Side Scatter Parameter by Flow Cytometry Correlate With Inferior Survival in Diffuse Large B-Cell Lymphoma. American Journal of Clinical Pathology, 2012, 137, 805-814.	0.4	12
264	Single Cell Phenotypic Profiling of 27 DLBCL Cases Reveals Marked Intertumoral and Intratumoral Heterogeneity. Cytometry Part A: the Journal of the International Society for Analytical Cytology, 2020, 97, 620-629.	1.1	12
265	Brentuximab vedotin plus doxorubicin, vinblastine, and dacarbazine in patients with advancedâ€stage, classical Hodgkin lymphoma: A prespecified subgroup analysis of highâ€risk patients from the ECHELONâ€1 study. Hematological Oncology, 2021, 39, 185-195.	0.8	12
266	A Novel Prognostic Model Based on Tumor Microenvironment Biology in Relapse Biopsies Predicts Post-Autologous Stem Cell Transplantation Outcomes in Classical Hodgkin Lymphoma. Blood, 2016, 128, 1093-1093.	0.6	12
267	Gene Expression Profiling of Microdissected Hodgkin Reed Sternberg Cells: Molecular Subtypes and Treatment Outcome Correlations.. Blood, 2009, 114, 268-268.	0.6	12
268	Tumor-associated antigen PRAME exhibits dualistic functions that are targetable in diffuse large B cell lymphoma. Journal of Clinical Investigation, 2022, 132, .	3.9	12
269	A Literature Review of Single Agent Treatment of Multiply Relapsed Aggressive Non-Hodgkin's Lymphoma. Leukemia and Lymphoma, 2002, 43, 975-982.	0.6	11
270	Cytogenetic findings in reactive lymphoid hyperplasia: Significance of non-clonal t(3;14) and t(3;22). American Journal of Hematology, 2002, 70, 133-138.	2.0	11

#	Article	IF	Citations
271	Lifetime Physical Activity and the Risk of Non-Hodgkin Lymphoma. Cancer Epidemiology Biomarkers and Prevention, 2015, 24, 873-877.	1.1	11
272	Maintenance rituximab following induction R-CHOP chemotherapy in patients with composite or discordant, indolent and aggressive, B-cell non-Hodgkin lymphomas. Haematologica, 2016, 101, e411-e414.	1.7	11
273	Gene Expression Signatures Predict Overall Survial in Diffuse Large B Cell Lymphoma Treated with Rituximab and Chop-Like Chemotherapy.. Blood, 2007, 110, 348-348.	0.6	11
274	Brentuximab Vedotin (SGN-35) in Patients with Relapsed or Refractory Systemic Anaplastic Large Cell Lymphoma: A Phase 2 Study Update. Blood, 2011, 118, 443-443.	0.6	11
275	Brentuximab Vedotin Combined with ABVD or AVD for Patients with Newly Diagnosed Advanced Stage Hodgkin Lymphoma: Long Term Outcomes. Blood, 2014, 124, 292-292.	0.6	11
276	Costâ€“effectiveness of rituximab in follicular lymphoma. Expert Review of Pharmacoeconomics and Outcomes Research, 2012, 12, 569-577.	0.7	10
277	Impact of time from diagnosis to initiation of curative-intent chemotherapy on clinical outcomes in patients with classical Hodgkin lymphoma. Leukemia and Lymphoma, 2016, 57, 872-879.	0.6	10
278	High-dose Benda-EAM versus BEAM in patients with relapsed/refractory classical Hodgkin lymphoma undergoing autologous stem cell transplantation. Bone Marrow Transplantation, 2019, 54, 481-484.	1.3	10
279	Hodgkin lymphoma: outsmarting HRS cells. Blood, 2020, 136, 2362-2364.	0.6	10
280	Older Patients (pts) with Previously Untreated Classical Hodgkin Lymphoma (cHL): A Detailed Analysis from the Phase 3 ECHELON-1 Study. Blood, 2018, 132, 1618-1618.	0.6	10
281	Accurate Diagnosis of Aggressive B Cell Non-Hodgkin Lymphomas Using Gene Expression Profiling of Formalin-Fixed, Paraffin-Embedded Tissues. Blood, 2014, 124, 3016-3016.	0.6	10
282	Non-Hodgkin Lymphoma Risk and Variants in Genes Controlling Lymphocyte Development. PLoS ONE, 2013, 8, e75170.	1.1	10
283	Ketoconazole Versus Nystatin as Prophylaxis Against Fungal Infection for Lymphoma Patients Receiving Chemotherapy. American Journal of Clinical Oncology: Cancer Clinical Trials, 1987, 10, 355-359.	0.6	9
284	New Strategies for the Treatment of Early Stages of Hodgkin's Lymphoma. Hematology/Oncology Clinics of North America, 2007, 21, 871-880.	0.9	9
285	Improved survival outcomes with the addition of rituximab to initial therapy for chronic lymphocytic leukemia: a comparative effectiveness analysis in the province of British Columbia, Canada. Leukemia and Lymphoma, 2018, 59, 1356-1363.	0.6	9
286	Validation of a simplified international prognostic score (IPSâ€3) in patients with advancedâ€stage classic Hodgkin lymphoma. British Journal of Haematology, 2020, 189, 122-127.	1.2	9
287	Resources-Stratified Guidelines for Classical Hodgkin Lymphoma. International Journal of Environmental Research and Public Health, 2020, 17, 1783.	1.2	9
288	Outcome of relapsed and refractory nodular lymphocyteâ€predominant Hodgkin lymphoma: a North American analysis. British Journal of Haematology, 2021, 192, 560-567.	1.2	9

#	Article	IF	Citations
289	Rapid Infusion Rituximab in Combination with Steroid Containing Chemotherapy Can Be Given Safely and Substantially Reduces Resource Utilization.. Blood, 2004, 104, 1407-1407.	0.6	9
290	Mechanisms of Bcl-2 Protein Expression in Diffuse Large B-Cell Lymphoma (DLBCL).. Blood, 2004, 104, 26-26.	0.6	9
291	FDG-PET Scan Guided Consolidative Radiation Therapy Optimizes Outcome In Patients with Advanced-Stage Diffuse Large B-Cell Lymphoma (DLBCL) with Residual Abnormalities on CT Scan Following R-CHOP. Blood, 2010, 116, 854-854.	0.6	9
292	Frontline Therapy with Brentuximab Vedotin Combined with ABVD or AVD in Patients with Newly Diagnosed Advanced Stage Hodgkin Lymphoma. Blood, 2012, 120, 798-798.	0.6	9
293	Five-Year Survival Data from a Pivotal Phase 2 Study of Brentuximab Vedotin in Patients with Relapsed or Refractory Systemic Anaplastic Large Cell Lymphoma. Blood, 2016, 128, 4144-4144.	0.6	9
294	Prognostic Significance of Bcl-2 Protein Expression and Bcl-2 Gene Rearrangement in Diffuse Aggressive Non-Hodgkin's Lymphoma. Blood, 1997, 90, 244-251.	0.6	9
295	Controversies and Future Directions in the Therapy of Lymphoma. Leukemia and Lymphoma, 1998, 30, 1-2.	0.6	8
296	A systematic evaluation of the ataxia telangiectasia mutated gene does not show an association with nonâ€Hodgkin lymphoma. International Journal of Cancer, 2007, 121, 1967-1975.	2.3	8
297	Autologous Stem Cell Transplantation Is Superior to Myeloablative Allogeneic SCT as a Salvage Therapy for Patients with Refractory/Relapsed Transformed Lymphoma. Blood, 2008, 112, 4459-4459.	0.6	8
298	Outcome in Unselected Patients with Relapsed/Refractory Diffuse Large B-Cell Lymphoma (DLBCL) Following R-CHOP When Stem Cell Transplantation Is Not Feasible. Blood, 2014, 124, 3069-3069.	0.6	8
299	Five-Year Survival Data Demonstrating Durable Responses from a Pivotal Phase 2 Study of Brentuximab Vedotin in Patients with Relapsed or Refractory Hodgkin Lymphoma. Blood, 2015, 126, 2736-2736.	0.6	8
300	Hodgkin lymphoma in the elderly, pregnant, and HIV-infected. Seminars in Hematology, 2016, 53, 203-208.	1.8	7
301	Nonrandom occurrence of lymphoid cancer types in 140 families. Leukemia and Lymphoma, 2017, 58, 2134-2143.	0.6	7
302	Leukocytoclastic vasculitis following lenalidomide during the treatment of follicular lymphoma. Leukemia and Lymphoma, 2017, 58, 711-714.	0.6	7
303	New Treatment Algorithms in Hodgkin Lymphoma: Too Much or Too Little?. American Society of Clinical Oncology Educational Book / ASCO American Society of Clinical Oncology Meeting, 2018, 38, 626-636.	1.8	7
304	Overall Survival Benefit for Patients with Relapsed Hodgkin Lymphoma Treated with Brentuximab Vedotin After Autologous Stem Cell Transplant. Blood, 2012, 120, 3701-3701.	0.6	7
305	A Clinicogenetic Risk Model (m7-FLIPI) Prospectively Identifies One-Half of Patients with Early Disease Progression of Follicular Lymphoma after First-Line Immunochemotherapy. Blood, 2015, 126, 333-333.	0.6	7
306	Prior Rituximab Reduces Relapse and Improves Survival Following High Dose Chemotherapy and Stem Cell Transplantation for Relapsed Composite Low and Intermediate Grade (Including Transformed) Lymphoma.. Blood, 2006, 108, 3662-3662.	0.6	7

#	Article	IF	Citations
307	The cured lymphoma patient. Postgraduate Medicine, 1982, 72, 53-59.	0.9	6
308	I. Hodgkin lymphoma: special challenges and solutions. Hematological Oncology, 2015, 33, 21-24.	0.8	6
309	Quantifying Benefit of Autologous Transplantation for Relapsed Follicular Lymphoma Patients via Instrumental Variable Analysis. Biology of Blood and Marrow Transplantation, 2016, 22, 941-948.	2.0	6
310	Outcome of patients with relapsed or refractory anaplastic large cell lymphoma who have failed brentuximab vedotin. Hematological Oncology, 2019, 37, 35-38.	0.8	6
311	Who Actually Detects Relapse in Hodgkin Lymphoma: Patient or Physician?.. Blood, 2004, 104, 3124-3124.	0.6	6
312	Mutations In MLL2 and MEF2B Genes In Follicular Lymphoma and Diffuse Large B-Cell Lymphoma. Blood, 2010, 116, 473-473.	0.6	6
313	The Outcome of Advanced Stage Nodular Lymphocyte Predominant Hodgkin's Lymphoma (NLPHL) Compared to Classical Hodgkin's Lymphoma (CHL): A Matched Pair Analysis. Blood, 2012, 120, 1531-1531.	0.6	6
314	Long-Term Remissions Observed in an Ongoing Phase 2 Study of Brentuximab Vedotin in Patients with Relapsed or Refractory Systemic Anaplastic Large Cell Lymphoma.. Blood, 2012, 120, 2745-2745.	0.6	6
315	Clinicopathological Analysis of Follicular Lymphoma with a Polyploid Karyotype. Leukemia and Lymphoma, 1998, 28, 383-389.	0.6	5
316	More Is Not Necessarily Better When Treating Hodgkin's Lymphoma. Journal of Clinical Oncology, 2011, 29, 4215-4216.	0.8	5
317	Chronic Lymphocytic Leukemia Patients With Deletion 11q Have a Short Time to Requirement of First-Line Therapy, But Long Overall Survival: Results of a Population-Based Cohort in British Columbia, Canada. Clinical Lymphoma, Myeloma and Leukemia, 2017, 17, 382-389.	0.2	5
318	Aberrant cytoplasmic expression of MHCII confers worse progression free survival in diffuse large B-cell lymphoma. Virchows Archiv Fur Pathologische Anatomie Und Physiologie Und Fur Klinische Medizin, 2017, 470, 113-117.	1.4	5
319	Frontline Therapy with Bendamustine and Rituximab (BR) in Follicular Lymphoma: Prognosis Among Patients with Progression of Disease By 24 Months (POD24) Is Poor with Majority Having Transformed Lymphoma. Blood, 2018, 132, 2873-2873.	0.6	5
320	Autologous Stem-Cell Transplant with a Rituximab Purge and Maintenance vs. Standard Chemotherapy for Mantle Cell Lymphoma: Extended Follow-Up of a Matched Pair Analysis.. Blood, 2006, 108, 3051-3051.	0.6	5
321	Follicular Non-Hodgkin Lymphoma Grade 3a and 3b Subtypes Exhibit Similar Clinical Behaviour and Treatment Outcome. Blood, 2008, 112, 3777-3777.	0.6	5
322	Clinical Significance of Genetic Aberrations in Diffuse Large B Cell Lymphoma. Blood, 2014, 124, 703-703.	0.6	5
323	Brentuximab vedotin with chemotherapy for stage III or IV Hodgkin lymphoma (HL): Impact of cycle 2 PET result on modified progression-free survival (mPFS).. Journal of Clinical Oncology, 2018, 36, 7539-7539.	0.8	5
324	Targeted Sequencing Reveals Novel Gene Mutations Associated with Transformation and Early Progression in Follicular Lymphoma. Blood, 2016, 128, 2919-2919.	0.6	5

#	Article	IF	Citations
325	Insulin Therapy in Diabetic Ketoacidosis. Annals of Internal Medicine, 1977, 86, 109.	2.0	4
326	Identification of Risk Factors in Patients Treated for First Relapse of Hodgkin's Disease. Leukemia and Lymphoma, 1994, 15, 189-200.	0.6	4
327	Treatment of Diffuse Large B-Cell Lymphoma: A Risk-Based Approach. Clinical Lymphoma and Myeloma, 2006, 7, S14-S19.	1.4	4
328	Genetic polymorphism at BCL2 as a predictor for rituximab, cyclophosphamide, doxorubicin, vincristine and prednisone efficacy in patients with diffuse large B-cell lymphoma. Haematologica, 2017, 102, e199-e202.	1.7	4
329	Outcome of limited-stage nodular lymphocyte-predominant Hodgkin lymphoma and the impact of a PET-adapted approach. Blood Advances, 2021, 5, 3647-3655.	2.5	4
330	CRIS: complete reconstruction of immunoglobulin V-D-J sequences from RNA-seq data. Bioinformatics Advances, 2021, 1, vbab021.	0.9	4
331	Outcome of Patients with Chemotherapy Refractory and Early Progressive Diffuse Large B Cell Lymphoma After R-CHOP Treatment. Blood, 2010, 116, 1751-1751.	0.6	4
332	Whole Transcriptome Sequencing Reveals Recurrent NOTCH1 Mutations in Mantle Cell Lymphoma. Blood, 2011, 118, 436-436.	0.6	4
333	Long-Term Survival Analyses of an Ongoing Phase 2 Study of Brentuximab Vedotin in Patients with Relapsed or Refractory Hodgkin Lymphoma. Blood, 2012, 120, 3689-3689.	0.6	4
334	ABVD Chemotherapy Results in Excellent Outcomes with Reduced Radiation Therapy Rates in Children, Adolescents and Young Adults with Hodgkin Lymphoma. Blood, 2015, 126, 2695-2695.	0.6	4
335	Phase 3 study of brentuximab vedotin plus doxorubicin, vinblastine, and dacarbazine (A+AVD) versus doxorubicin, bleomycin, vinblastine, and dacarbazine (ABVD) as front-line treatment for advanced classical Hodgkin lymphoma (HL): Echelon-1 study.. Journal of Clinical Oncology, 2014, 32, TPS8613-TPS8613.	0.8	4
336	Outcomes of Hodgkin variant Richter transformation in chronic lymphocytic leukaemia and small lymphocytic lymphoma in British Columbia. British Journal of Haematology, 2022, 198, 684-692.	1.2	4
337	Advanced-Stage Hodgkin Lymphoma. Cancer Journal (Sudbury, Mass), 2018, 24, 230-236.	1.0	3
338	Birth Order, Sibship Size, Childhood Environment and Immune-Related Disorders, and Risk of Lymphoma in Lymphoid Cancer Families. Cancer Epidemiology Biomarkers and Prevention, 2020, 29, 1168-1178.	1.1	3
339	Transformed Lymphoma: Incidence and Long-Term Outcome.. Blood, 2004, 104, 3253-3253.	0.6	3
340	Relapse Patterns and Subsequent Outcomes of Patients Treated on the NCIC CTG HD.6 (ECOG JHD06) Randomized Trial Evaluating ABVD Alone in Patients with Limited Stage Hodgkin Lymphoma (HL).. Blood, 2005, 106, 817-817.	0.6	3
341	FDG-PET Guided Consolidative Radiotherapy in Patients with Advanced Stage Hodgkin Lymphoma with Residual Abnormalities on Post Chemotherapy CT Scan.. Blood, 2007, 110, 213-213.	0.6	3
342	The Architecural Pattern of FOXP3+ T Cells Predicts Risk of Transformation in Patients with Follicular Lymphoma (FL).. Blood, 2007, 110, 358-358.	0.6	3

#	Article	IF	Citations
343	HLA-DR Protein Expression Correlates with Non-Neoplastic T-Cell Infiltration and Predicts Survival in Patients with Primary Mediastinal Large B Cell Lymphoma (PMBCL) Treated with CHOP Chemotherapy.. Blood, 2009, 114, 133-133.	0.6	3
344	Diffuse Large B-Cell Lymphoma with Testicular Involvement: Outcome and Risk of CNS Relapse in the Rituximab Era. Blood, 2011, 118, 780-780.	0.6	3
345	A Phase 1 -2 Study of Brentuximab Vedotin (Bv) and Bendamustine (B) in Patients with Relapsed or Refractory Hodgkin Lymphoma (HL) and Anaplastic Large T-Cell Lymphoma (ALCL). Blood, 2014, 124, 3084-3084.	0.6	3
346	Outcome of Observation As Initial Strategy in Patients with Mantle Cell Lymphoma. Blood, 2015, 126, 2699-2699.	0.6	3
347	Second Malignancies in Patients With Hairy Cell Leukemia in British Columbia: A 20-Year Experience. Blood, 1998, 92, 1160-1164.	0.6	3
348	Is There a Role for MACOP-B in the Treatment of Diffuse Large Cell Lymphoma?. Leukemia and Lymphoma, 1993, 10, 85-89.	0.6	2
349	The Case for Chemotherapy Alone for Limited-Stage Hodgkin's Lymphoma. Oncologist, 2012, 17, 1011-1013.	1.9	2
350	Identification of a novel non-immunoglobulin/MYC translocation t(8;12)(q24;p12) involving the LRMP gene in a primary B-cell lymphoma. A case report. Leukemia Research, 2012, 36, e22-e24.	0.4	2
351	Treatment of NLPHL. Blood, 2013, 122, 4288-4289.	0.6	2
352	Development and characterization of a Mantle Cell Lymphoma Cell Bank in the American Type Culture Collection. Leukemia and Lymphoma, 2015, 56, 2114-2122.	0.6	2
353	Response assessment in lymphoma: Concordance between independent central review and local evaluation in a clinical trial setting. Clinical Trials, 2016, 13, 545-554.	0.7	2
354	Tattoos and Hematologic Malignancies in British Columbia, Canada. Cancer Epidemiology Biomarkers and Prevention, 2020, 29, 2093-2095.	1.1	2
355	Anaplastic large cell lymphoma: a clinicopathologic analysis. Hematological Oncology, 1999, 17, 137-148.	0.8	2
356	Molecular and Genetic Characterization of MHC Deficiency Identifies EZH2 As a Therapeutic Target for Restoring MHC Expression in Diffuse Large B-Cell Lymphoma. Blood, 2018, 132, 1560-1560.	0.6	2
357	Hematopoietic Stem Cell Transplant (HSCT) as Primary Treatment for T-Cell Lymphobastic Lymphoma (T-LBL) : An Intention to Treat Analysis.. Blood, 2004, 104, 900-900.	0.6	2
358	Allogeneic Stem Cell Transplantation as Treatment for Relapsed and High-Risk Peripheral T-Cell Lymphoma.. Blood, 2007, 110, 3040-3040.	0.6	2
359	LMO2 Protein Expression Predicts Survival in Patients with Diffuse Large B-Cell Lymphoma in the Pre- and Post-Rituximab Treatment Eras.. Blood, 2007, 110, 52-52.	0.6	2
360	CARD11 as an Oncogene in Diffuse Large B Cell Lymphoma.. Blood, 2007, 110, 692-692.	0.6	2

#	Article	IF	Citations
361	Deletion in Chromosome 17p12 and Gains in Chromosome 9q33.3 by Array Comparative Hybridization Are Associated with R-CHOP Treatment Failure in Patients with Diffuse Large B Cell Lymphoma. Blood, 2008, 112, 477-477.	0.6	2
362	Number of Lymphoma-Associated-Macrophages (LAM) Is An Independent Predictor of Survival in Patients with Mantle Cell Lymphoma (MCL).. Blood, 2009, 114, 3944-3944.	0.6	2
363	Incorporation of ABVD Increases Cure Rates of Patients with Limited Stage Nodular Lymphocyte Predominant Hodgkin Lymphoma (NLPHL). Blood, 2010, 116, 3887-3887.	0.6	2
364	Hodgkin Lymphoma Patients with Stage II B or Stage II Bulky Disease Have Advanced Disease and Should Not Be Included In Limited Stage Trials. Blood, 2010, 116, 417-417.	0.6	2
365	Final Analysis of a Randomized Comparison of ABVD Chemotherapy with a Strategy That Includes Radiation Therapy (RT) in Patients with Limited-Stage Hodgkin Lymphoma (HL): NCIC CTG/ECOG HD.6. Blood, 2011, 118, 590-590.	0.6	2
366	Survival of Peripheral T-Cell Lymphomas (PTCLs) Patients Following Relapse: Spectrum of Disease and Rare Long-Term Survivors. Blood, 2011, 118, 96-96.	0.6	2
367	An International Collaborative Study of Outcome and Prognostic Factors in Patients with Secondary CNS Involvement By Diffuse Large B-Cell Lymphoma. Blood, 2016, 128, 1874-1874.	0.6	2
368	Prognostic significance of the proliferation signature in mantle cell lymphoma measured using digital gene expression in formalin-fixed paraffin-embedded tissue biopsies.. Journal of Clinical Oncology, 2016, 34, 7510-7510.	0.8	2
369	EFS24 as a predictor of outcome in a population-based cohort of patients with DLBCL in British Columbia (BC).. Journal of Clinical Oncology, 2016, 34, 7569-7569.	0.8	2
370	CD20 Mutations at the Rituximab Binding Site Are Rare and Are Not a Significant Cause of R-CHOP Resistance in Patients with De Novo Diffuse Large B-Cell Lymphoma.. Blood, 2007, 110, 686-686.	0.6	2
371	Concurrent BCL2 and MYC Protein Expression by Immunohistochemistry Determines Clinical Outcome In DLBCL Patients Treated with R-CHOP. Blood, 2010, 116, 2005-2005.	0.6	2
372	Hepatic Dysfunction During and After Lymphoma Chemotherapy in Patients With Hepatitis C. Journal of Clinical Gastroenterology, 2006, 40, 636-638.	1.1	1
373	Clinical Impact of Pathology Reviews of Outside Material: A Patient-Focused Approach. Journal of Clinical Oncology, 2011, 29, 4212-4213.	0.8	1
374	Sex- and Subtype-Specific Analysis of H2AFX Polymorphisms in Non-Hodgkin Lymphoma. PLoS ONE, 2013, 8, e74619.	1.1	1
375	Chemotherapy Only in Early Stage Hodgkin Lymphoma: More Relapses but the Same Survival â€“ What to Do?. Current Hematologic Malignancy Reports, 2014, 9, 217-221.	1.2	1
376	Is the lymphoma better? Not easy to determine. Blood, 2016, 128, 2481-2482.	0.6	1
377	Immune Checkpoint Inhibition: A New Era in Lymphoma Treatment. Journal of Oncology Practice, 2016, 12, 109-110.	2.5	1
378	Hodgkin lymphoma, treatment and thrombosis: a dangerous mix. Annals of Oncology, 2019, 30, 1192-1193.	0.6	1

#	Article	IF	Citations
379	Molecular Features of Primary Central Nervous System Lymphoma in a Large Tissue Microarray. Blood, 2018, 132, 348-348.	0.6	1
380	The Double-Hit Gene Expression Signature Defines a Clinically and Biologically Distinct Subgroup within GCB-DLBCL. Blood, 2018, 132, 921-921.	0.6	1
381	Prolonged Overall Survival (OS) in a Subset of Responders to the Combination of Brentuximab Vedotin (Bv) and Bendamustine (B) in Heavily Treated Patients with Relapsed or Refractory Hodgkin Lymphoma (HL): Results of an International Multi- Center Phase I/II Experience. Blood, 2018, 132, 2907-2907.	0.6	1
382	Outcome of Limited Stage Nodular Lymphocyte Predominant Hodgkin Lymphoma (NLPHL) and Evaluation of a PET-Adapted Approach. Blood, 2019, 134, 2845-2845.	0.6	1
383	Lymphoma-Associated Macrophage (LAM) Content Is an Independent Predictor of Survival in Patients with Follicular Lymphoma (FL).. Blood, 2004, 104, 3259-3259.	0.6	1
384	Survival of Limited Stage Peripheral T-Cell Lymphoma Is Similar To Diffuse Large B-Cell Lymphoma.. Blood, 2005, 106, 2817-2817.	0.6	1
385	Insights into Disease Evolution of Transformed Follicular Lymphoma Derived from Cytogenetics.. Blood, 2005, 106, 604-604.	0.6	1
386	Clinicopathologic Subtypes of Mantle Cell Lymphoma (MCL) Show Distinct Patterns of Genetic Copy Number Alteration.. Blood, 2006, 108, 2049-2049.	0.6	1
387	Comparison of Outcome Between Refractory/Relapsed De Novo Diffuse Large B-Cell and Transformed Lymphoma Using Related and Unrelated Allogeneic Hematopoietic SCT.. Blood, 2008, 112, 2173-2173.	0.6	1
388	The Percentage of Cytotoxic T-Cells in Mantle Cell Lymphoma (MCL) Biopsies Predicts Response to Rituximab.. Blood, 2009, 114, 2923-2923.	0.6	1
389	Identification of Genes Frequently Mutated In FL and DLBCL with Transcriptome, Genome and Exome Sequencing. Blood, 2010, 116, 804-804.	0.6	1
390	A Gene Expression Signature in Diagnostic Formalin Fixed Paraffin Embedded Tissue Predicts Overall Survival in Locally Advanced and Advanced Stage Classical Hodgkin Lymphoma â€“ a Correlative Study From the E2496 Intergroup Trial. Blood, 2011, 118, 430-430.	0.6	1
391	FAS Mutations Accelerate Lymphoma Growth and Induce Therapeutic Resistance. Blood, 2014, 124, 3018-3018.	0.6	1
392	Rituximab with High Dose Methotrexate in the Management of Primary Central Nervous System Diffuse Large B-Cell Lymphoma. Blood, 2014, 124, 3090-3090.	0.6	1
393	The Absolute Number of Extranodal Sites Detected By PET-CT Is a Powerful Predictor of Secondary Central Nervous System Involvement in Patients with Diffuse Large B-Cell Lymphoma Treated with R-CHOP. Blood, 2015, 126, 3905-3905.	0.6	1
394	Both Discordant and Concordant Bone Marrow (BM) Involvement Predict for a Poorer Outcome Independent of the IPI in Patients with Diffuse Large B-Cell Lymphoma (DLBCL) Treated with R-CHOP.. Blood, 2007, 110, 1559-1559.	0.6	1
395	Molecular Signatures Implicate Innate Immune Cells, Fibrosis, and Angiogenesis in Survival Following R-CHOP Treatment of Diffuse Large B Cell Lymphoma. Blood, 2008, 112, 475-475.	0.6	1
396	Genetic Alterations Detected by High-Resolution Array Comparative Genomic Hybridization in Microdissected HRS Cells Correlate with Treatment Outcome in Classical Hodgkin Lymphoma. Blood, 2008, 112, 522-522.	0.6	1

#	Article	IF	Citations
397	TNFRSF14 Is Mutated in a Subset of Follicular Lymphoma and Correlated with Inferior Prognosis.. Blood, 2009, 114, 1919-1919.	0.6	1
398	Protein Tyrosine Phosphatase Type-1 (PTPN1) Is Frequently Mutated In Primary Mediastinal B Cell Lymphoma and Hodgkin Lymphoma. Blood, 2013, 122, 242-242.	0.6	1
399	Role of Bone Marrow Biopsy in the Staging of Diffuse Large B-Cell Lymphoma in the PET/CT Era. Blood, 2014, 124, 2960-2960.	0.6	1
400	Prognostic Impact of Extranodal Diffuse Large B-Cell Lymphoma in the Era of Immunochemotherapy and PET/CT Staging. Blood, 2014, 124, 1630-1630.	0.6	1
401	Outcomes in Adolescents and Young Adults (AYA) with Hodgkin Lymphoma (HL) Treated on US Cooperative Group Protocols: An Adult Intergroup (E2496) and Children's Oncology Group (COG) Tj ETQq1 1 0.784314 rgBT /Overlock	0.6	1
402	Frequent Genetic Alterations of PI3K-AKT Pathway and Their Clinical Significance in Germinal Center B-Cell-like Diffuse Large B-Cell Lymphoma. Blood, 2016, 128, 607-607.	0.6	1
403	Outcome of elderly patients with classical Hodgkin lymphoma (HL) in British Columbia.. Journal of Clinical Oncology, 2020, 38, 8031-8031.	0.8	1
404	Primary Testicular Lymphoma. Journal of Urology, 1987, 137, .	0.2	0
405	Reply to D.E. Roos. Journal of Clinical Oncology, 2012, 30, 1147-1147.	0.8	0
406	Interview: Learning from lymphocytes: a career studying lymphoid cancer. International Journal of Hematologic Oncology, 2014, 3, 15-17.	0.7	0
407	Introduction From the Guest Editor: Hodgkin Lymphoma. Cancer Journal (Sudbury, Mass), 2018, 24, 205-205.	1.0	0
408	Letter comments on a published article in the New England Journal of Medicine. European Journal of Cancer, 2018, 104, 250-251.	1.3	0
409	To treat or not to treat, that is the NLPHL question. Blood, 2019, 133, 2113-2114.	0.6	0
410	HLA-DR Protein Status Predicts Survival in Patients with Diffuse Large B Cell Lymphoma (DLBCL) Treated with the MACOP-B Chemotherapy Regimen.. Blood, 2004, 104, 3273-3273.	0.6	0
411	Acceptable Outcomes for Patients Receiving Allogeneic Hematopoietic Stem Cell Transplantation (AlloSCT) for Relapsed Aggressive Non-Hodgkinâ€™s Lymphoma (NHL).. Blood, 2004, 104, 3325-3325.	0.6	0
412	High Cyclin D1 Expression Is Associated with Increased Proliferation Rate and Decreased Survival in Mantle Cell Lymphoma (MCL) and Is Caused by Genomic Deletions and Mutations that Enhance Stability of Cyclin D1 mRNA.. Blood, 2004, 104, 697-697.	0.6	0
413	Primary Central Nervous System Lymphoma of T Cell Origin: A Descriptive Analysis of 45 Cases from the International PCNSL Collaborative Group.. Blood, 2004, 104, 1372-1372.	0.6	0
414	Long Term Results of Myeloablative Allogeneic Stem Cell Transplantation Using Related and Unrelated Donors in Patients with Relapsed Composite Low and Intermediate Grade (Including Transformed) Lymphoma.. Blood, 2006, 108, 3139-3139.	0.6	0

#	Article	IF	Citations
415	Outcome in Patients with Diffuse Large B-Cell Lymphoma (DLBCL) Treated with CHOP-R Can Be Predicted by Stage and Serum Lactate Dehydrogenase (LDH) Level.. Blood, 2006, 108, 2739-2739.	0.6	0
416	Bone Marow (BM) Involvement in Diffuse Large B Cell Lymphoma (DLBCL): Clinical Impact of Discordant Disease.. Blood, 2006, 108, 2031-2031.	0.6	0
417	Myeloablative Allogeneic Stem Cell Transplantation for Relapsed Composite Low and Intermediate Grade Lymphoma Is Not Superior to Autologous Stem Cell Transplantation - Reduced Relapse Risk Is Offset by Higher Treatment Related Mortality.. Blood, 2006, 108, 3039-3039.	0.6	0
418	Long Term Follow-Up Results for Patients with Hodgkin Lymphoma after First Remission of Longer Than Ten Years: A Population Based Study of 954 Patients from the British Columbia Cancer Agency.. Blood, 2006, 108, 2269-2269.	0.6	0
419	Correlation of DNA Copy Number, Gene Expression, Protein Expression and Clinical Outcome in a Group of Patients with Diffuse Large B Cell Lymphoma (DLBCL) Treated with CHOP Plus Rituximab (CHOP-R).. Blood, 2006, 108, 2027-2027.	0.6	0
420	Vascularization Predicts Overall Survival (OS) & Risk of Transformation (RT) in Uniformly Treated Patients with Follicular Lymphoma (FL).. Blood, 2007, 110, 184-184.	0.6	0
421	Impact of Comorbidity Index on Outcome with Allogeneic Hematopoetic Stem Cell Transplantation for Chronic Lymphocytic Leukemia. Blood, 2008, 112, 3305-3305.	0.6	0
422	Genome-Wide Expression Profiling Predicts Treatment Outcome in Classical Hodgkin Lymphoma. Blood, 2008, 112, 520-520.	0.6	0
423	Base-Pair Resolution of Somatic and Germline-Derived Genome Rearrangement Breakpoints in Follicular Lymphoma.. Blood, 2009, 114, 439-439.	0.6	0
424	Exposure to Novel Agents Increases Post Relapse Survival in Patients with High Risk Myeloma Defined by Early Relapse (<12 months).. Blood, 2009, 114, 2872-2872.	0.6	0
425	Fludarabine (F) and Rituximab (R) (FR) as Initial Therapy for Symptomatic Chronic Lymphocytic Leukemia (CLL) or Small Lymphocytic Lymphoma (SLL): Population-Based Experience Matches Clinical Trials.. Blood, 2009, 114, 2363-2363.	0.6	0
426	The Management of Hodgkin Lymphoma During Pregnancy. , 2011, , 241-248.		0
427	The Prognosis of Limited Stage Peripheral T-Cell Lymphoma (PTCL): A Population-Based Analysis and Comparison to Diffuse Large B-Cell Lymphoma (DLBCL). Blood, 2010, 116, 4129-4129.	0.6	0
428	Fludarabine and Rituximab (FR) Is a Safe and Effective Treatment Alternative for Relapsed or Refractory Hairy Cell Leukemia (HCL). Blood, 2010, 116, 2454-2454.	0.6	0
429	Recurrent DNA Mutations In Non-Hodgkin Lymphomas Reveal Candidate Therapeutic Targets. Blood, 2010, 116, 632-632.	0.6	0
430	Front-Line Therapy with Rituximab, Cyclophosphamide, Vincristine, and Prednisone (R-CVP) Followed by 2 Years of Rituximab Maintenance for Follicular Lymphoma (FL) Is Associated with Excellent Outcomes and Improved Progression-Free Survival (PFS) In Comparison to No Maintenance. Blood, 2010, 116, 1803-1803.	0.6	0
431	BCL2 Is Highly Mutated In Diffuse Large B-Cell Lymphoma. Blood, 2010, 116, 4187-4187.	0.6	0
432	CSF1R Expression of Hodgkin Reed Sternberg Cells Is Associated with the Number of Macrophages in the Tumor Microenvironment and Is Correlated with Treatment Outcome. Blood, 2011, 118, 427-427.	0.6	0

#	Article	IF	Citations
433	Chemoresistance Can Be Reliably Overcome with High-Dose Therapy and Autologous Stem Cell Transplantation (HDT/ASCT) for Relapsed and Refractory Hodgkin's Lymphoma. Blood, 2011, 118, 2022-2022.	0.6	0
434	Population Survey of Mantle Cell Lymphoma (MCL) in British Columbia (BC) â€“ A Heterogeneous Disorder with Improved Outcomes in the Modern Era. Blood, 2012, 120, 1602-1602.	0.6	0
435	FAS Mutations Are Associated with Therapeutic Resistance in Follicular Lymphoma. Blood, 2012, 120, 1549-1549.	0.6	0
436	Prognostic Factors in Patients with HIV-Associated Hodgkin Lymphoma: An Analysis of 199 Cases. Blood, 2012, 120, 1528-1528.	0.6	0
437	Large-Scale High Resolution Integration of Copy Number and Gene Expression in DLBCL Reveals Focal and Frequent Deletions in Chromatin Modifying Genes with Outcome Correlation. Blood, 2012, 120, 295-295.	0.6	0
438	Abstract A10: MLL2 interactions in follicular and diffuse large B-cell lymphoma. , 2013, , .		0
439	Genetic Alterations In Immune Cell Crosstalk Genes In Diffuse Large B-Cell Lymphoma Predict Survival. Blood, 2013, 122, 500-500.	0.6	0
440	Determining Cell-Of-Origin Subtypes In Diffuse Large B-Cell Lymphoma Using Gene Expression Profiling On Formalin-Fixed Paraffin-Embedded Tissue â€“ An L.L.M.P.P. Project. Blood, 2013, 122, 73-73.	0.6	0
441	The Use Of GDP (Gemcitabine, Dexamethasone and Cisplatin) in The Primary Therapy Of Peripheral T-Cell Lymphomas. Blood, 2013, 122, 1804-1804.	0.6	0
442	The outcome of patients with "nodal" peripheral T-cell lymphomas in a complete response following standard chemotherapy.. Journal of Clinical Oncology, 2014, 32, 8555-8555.	0.8	0
443	Abstract 959: FAS mutations induce therapeutic resistance in non-Hodgkin lymphomas. , 2014, , .		0
444	Analysis of Relapse Biopsies in Classical Hodgkin Lymphoma Reveals Correlations with Outcome after Autologous Stem Cell Transplantation. Blood, 2014, 124, 136-136.	0.6	0
445	Cell-of-Origin Subtype Classification of Diffuse Large B-Cell Lymphoma Using the Lymph2Cx Assay Retains Relevance in the Context of BCL2 and MYC Expression Status. Blood, 2014, 124, 1667-1667.	0.6	0
446	Primary Cutaneous Anaplastic Large Cell Lymphoma: The British Columbia Cancer Agency Experience. Blood, 2014, 124, 3076-3076.	0.6	0
447	Maintenance Rituximab Following R-CHOP Chemotherapy in Patients with Composite or Discordant, Indolent and Aggressive, B-Cell Non-Hodgkin Lymphomas. Blood, 2015, 126, 3950-3950.	0.6	0
448	An International Assessment of Event-Free Survival at 24 Months (EFS24) and Subsequent Survival in Peripheral T-Cell Lymphoma. Blood, 2016, 128, 920-920.	0.6	0
449	Outcome of Hodgkin Lymphoma after Progression Following Autologous Stem Cell Transplantation. Blood, 2016, 128, 2994-2994.	0.6	0
450	Divergent Modes of Tumor Evolution Underlie Histological Transformation and Early Progression of Follicular Lymphoma. Blood, 2016, 128, 1091-1091.	0.6	0

#	Article	IF	Citations
451	Outcome of Patients with Peripheral T-Cell Lymphoma Undergoing Allogeneic Stem Cell in British Columbia. Blood, 2016, 128, 5852-5852.	0.6	0
452	Population-Based Survival Outcomes in Adult Patients with Burkitt Lymphoma (BL) Treated with Cyclophosphamide, Vincristine, Doxorubicin, High-Dose Methotrexate (CODOX-M)/Ifosfamide, Etoposide and High-Dose Cytarabine (IVAC) Plus or Minus Rituximab (R) in British Columbia (BC), Canada. Blood, 2016, 128, 1113-1113.	0.6	0
453	Abstract 2445: Integrative genetic analysis identifies therapeutic relevance of cell of origin-specific genetic alterations in diffuse large B-cell lymphoma. , 2017, , .		0
454	Validation of a Simplified International Prognostic Score (IPS-3) in Patients with Advanced Stage Hodgkin Lymphoma. Blood, 2018, 132, 2916-2916.	0.6	0
455	Hodgkin Variant of Richter's Transformation (HvRT) Among Chronic Lymphocytic Leukemia (CLL)/Small Lymphocytic Lymphoma (SLL) Patients in British Columbia (BC), Canada. Blood, 2020, 136, 13-15.	0.6	0
456	Cardiac Morbidity in Adolescents and Young Adult Survivors of Hodgkin Lymphoma. Blood, 2020, 136, 18-19.	0.6	0
457	Real-World Characterization of Ibrutinib Therapy for Chronic Lymphocytic Leukemia (CLL) and Small Lymphocytic Lymphoma (SLL) Patients in British Columbia (BC). Blood, 2020, 136, 33-34.	0.6	0
458	Cost-Effectiveness of Molecularly Guided Treatment in Diffuse Large B-Cell Lymphoma (DLBCL) in Patients under 60. Cancers, 2022, 14, 908.	1.7	0
459	Abstract 3480:TMEM30Aloss-of-function mutations drive lymphomagenesis and confer therapeutically exploitable vulnerability in B-cell lymphoma. , 2019, , .		0
460	Radioimmunotherapy for orbital marginal zone lymphoma: a retrospective review. Leukemia and Lymphoma, 2022, , 1-4.	0.6	0
461	Outcomes after initial refusal of curative treatment in patients with classic Hodgkin lymphoma. Leukemia and Lymphoma, 2022, 63, 2739-2742.	0.6	0